Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neptunus Bioengineering Holdings To Transfer Beidouxing Pharmaceutical

This article was originally published in PharmAsia News

Executive Summary

Neptunus Bioengineering Holdings plans to transfer its 100 percent stake in Changchun Beidouxing Pharmaceutical for RMB 40 million to Texas Petroleum. In addition, the company and its subsidiary Neptunus Interlong Bio-technique will sign a letter of intent on equity transfer and assets acquisition. To beef up Interlong's profit-making capability, Neptunus Bioengineering and its holding subsidiary Neptunus Medicine intend to sell their respective 75 percent and 5 percent stakes in Fuzhou Neptunus Futao Pharmaceuticals to Interlong. Interlong will on its part transfer its interferon and interleukin business to Neptunus Medicine. (Click here for more - Chinese Language)

You may also be interested in...



Sun's Halol Site Faces FDA Action

FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.

Dr Reddy’s And Hikma Win Big On US Vascepa Patents

In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.

Manipulating Metabolism: Lilly Links With UK Biotech Sitryx

Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.

UsernamePublicRestriction

Register

SC071267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel